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ABSTRACT: Antihemoroid®suppository has been produced commercially by PT. Kimia Farma, Indone-
sia. For QC purposes, a separated densitometric method for analysis of its active ingredients, lidocaine 
hydrochloride and hexachlorophene, was applied. The objective of this study was obtaining more effi-
cient analysis method of LH and HC, therefore an HPLC procedure has been developed for the determi-
nation of both compounds simultaneously. AYMC-Triart C18 column was used with a gradient mobile 
phase consisting of acetonitrile and phosphate buffer 0.05 M (pH 6.0). Quantitative evaluation was per-
formed at 220 nm. Method validation was performed according to the new methods of USP 41. Result 
showed that the HPLC method was simple, accurate, precise, and robust. The HPLC method can be applied 
in simultaneous determination of LH and HC in suppositories as a QC tool in the pharmaceutical industries.
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1. Introduction
PT. Kimia Farma (Persero) Tbk., Plant 
Watudakon, Jombang, Indonesia, produced 
antihemoroid®suppository which have indica­
tion as anti-hemorrhoids; the active ingredi­
ents were lidocaine HCl (LH), hexachlorophene 
(HC), bismuth subgallate and zinc oxide; the 
registration number of antihemoroid® was GK­
L1732302453A1 [1]. 
Presently, a separated densitometric methods 
for analyzing of LH and HC were applied for the 
QC purposes at PT. Kimia Farma, Indonesia. Sto­
janovicet al. [2] reported simultaneously deter­
mination of LH and hydrocortisone in supposi­
tories by HPLC. Method of analysis of mixtures 
LH, dexamethasone acetate, calciumdobesilate, 
butyl hydroxy anisole, and degradation product 
of hydroquinone in suppositories and ointment 
by HPLC were also reported [3]. Analysis of mix­
tures of LH, betamethasone valerate, and phenyl­
ephrine in suppositories by HPLC was also des-
cribed [4]. Determination of LH with other active 
pharmaceutical ingredient (API) in injections and 
mouthwash were also published previously [5-6]. 
Gagliardi et al. [7] reported the analysis of mix­
tures of HC and other preservatives in cosmetic 
preparations by HPLC. 
There is no official method of simultaneous 
determination for both LH and HC in Indonesian 
Pharmacopeia V [8] and United States Pharma­
copoeia 41 [9]. Unfortunately, no publications re­
ported simultaneous assay of LH and HC in phar­
maceutical preparations including suppositories 
by HPLC. The objective of this present work is to 
develop a valid and simple HPLC method, that 
can be applied for analyzing LH and HC simul-
ta n eously in suppositories. The proposed HPLC 
method was validated according to the new gui­
dance of USP 41 [10-13].
2. Materials and methods
2.1.  Materials and chemicals 
LH (Apex Healthcare Limited, Gujarat, India), 
HC (Tokyo Chemical Industry, Tokyo, Japan), 
bismuth subgallate (Anmol Chemicals, Gujarat, 
India), zinc oxide (PT. Indoxide Surabaya, In­
donesia), polyethylene glycol (Clariant, Bern, 
Swiss), glycerol (IOI Oleochemical, Penang, Ma­
laysia), subanal EF-37 and sub anal EF- 42 (Dott. 
Bonapace & C, Via Salerno, Italy), white petrola­
tum (Rose Polymer Co., Ltd., Tehran, Iran), castor 
oil (Thai Castor Oil Industries, Co., Ltd., Bangkok, 
Thailand); all of pharmaceutical grade substanc­
es were used directly for preparation of labora­
tory-made (LM) suppositories and standard so­
lutions. Other chemicals were acetonitrile HPLC 
grade (Merck, Darmstadt, Germany), methanol 
HPLC grade (Merck, Darmstadt, Germany), diso­
dium hydrogen phosphate dehydrates for analy­
sis (Merck, Darmstadt, Germany), orthophospho­
ric acid 85% analytical grade (Merck, Darmstadt, 
Germany). 
2.2.  Preparation of laboratory-made (LM) sup- 
           positories
The composition (weight %) of suppository 
according to the claim label was bismuth 
subgallate 6%, zinc oxide 7.5%, LH 0.5% and 
HC 0.125%, polyethylene glycol 0.93%, glycerol 
3.2%, subanal EF-37 23.08%, subanal EF-42 
37.43%, white petrolatum 18.15%, castor oil 
3.0%. All excipients were weighed and melted at 
60oC into homogeneous mixture, LH and HC were 
added, and then formed into suppository and 
cooled in a refrigerator at -18oC. The weight of LM 
suppository was 2.00 g.
The laboratory-made (LM) suppository 
preparation was prepared containing three 
different concentration levels i.e. 80% (LM1), 
100% (LM2), and 120% (LM3) of the claim label; 
concentration of LH in LM1-3 were 8 mg, 10 mg, 
and 12 mg, respectively; whereas concentration 
of HC in LM1-3 were 2 mg, 2.5 mg, and 3 mg, 
respectively. These LM suppositories were used 
for accuracy and precision determinations.
2.3. Preparation of standard solutions
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The stock solutions were prepared by 
dissolving of LH and HC (accurately weighed 
circa 25.000 mg) in 25.0 and 10.0 ml of methanol, 
respectively. 2.5 ml of the HC solution was diluted 
to 25.0 mL using methanol. The stock solutions 
were prepared in duplicate daily.
2.4. LM suppositories extractions 
LM suppositories were cut into small pieces 
(circa 0.5 cm) and a part of them were accurately 
weighed (circa 2.00 g) and transferred into a 15.0 
ml centrifuge tube containing 5.0 ml of methanol 
then heated in a water bath at 60oC (5 min), 
vortexed (1 min), then sonicated (5 min) and 
centrifuged at 4000 rpm (10 min). The solutions 
were cooled in a refrigerator at -18oC (30 min) 
and filtered by using Whatman®filter papers. The 
supernatants were then diluted into 10.0 ml and 
the solutions were filtered through MF-Millipore 
membrane filter 0.45 µm before injected (10µl) 
into an HPLC.
2.5. HPLC instrumentation and condition
The HPLC system used in this work was 
comprised of a Waters Alliance 2695 HPLC 
system (Massachusetts, USA) equipped with a 
UV/Vis detector, a binary pump, auto sampler, 
and column heater. The analysis was carried 
out on a YMC-Triart C18 column (5 µm, 150 
mm x 4.6 mm) with a flow rate of 1.0 ml/min. A 
modified gradient mobile phase from previous 
publications [2,7], consisted of acetonitrile and 
buffer solution, was utilized (Table 1). The buffer 
solution consisted of 0.05 M Na2HPO4.2H2O and 
adjusted to pH 6.0 with 85% H3PO4. Detector and 
temperature of column heater were set at 220 nm 
and 25.0oC, respectively. The mobile phase was 
prepared daily and filtered through 0.45 µm and 
ultrasonicated for 15 min. The chromatograms 
were recorded and integrated using EmpowerTM3 
(2010) chromatographic data software (Waters).
2.6. Method development and validation
This proposed HPLC method was validated 
for selectivity, linearity, accuracy, precision, and 
robustness by the modified methods of USP 41 
[10-13]. 
2.6.1. Selectivity
The selectivity of the method was determined 
by injection of  standard solutions, extracts of 
placebo and LM2 into HPLC. Due to the lack of 
photodiode-array detector at PT. Kimia Farma, the 
purity checks of the analyte peaks were evaluated 
by calculating the RSD of TI (tailing factor) and 
total plate number (N), which were measured 
at six different wave lengths according to the 
previous publication [14]. System suitability was 
evaluated according to the monograph of LH 
[8,9]. Stability of standards and samples were 
evaluated in 24 hours [14]. 
2.6.2. Linearity 
For linearity study and calibrations, various 
standard solutions were prepared daily from the 
two stock solutions (60 to 150% of the expec-
ted concentrations, for LH: 600.0, 800.0, 1000.0, 
1200.0, and 1500.0 µg/ml; HC: 160.0, 200.0, 
250.0, 300.0, and 360.0 µg/ml), each of these so­
Table 1. Composition of gradient mobile phase (v/v) 
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lution (10µl) was injected into the HPLC.
2.6.3. Accuracy and precision
Accuracy and precision evaluations were 
performed on LM1, LM2, and LM3 in 6 replicates 
in three different days (n total = 6 x 3 x 3 = 54 
samples). The required specification range of the 
product that described in the analytical target 
profile (ATP) of this present work, was set from 95 
to 105% of the claim label (± 5%), with a precision 
of 2%. If the total error of the manufacturing 
process was assumed of maximum of 2%, the 
corrected specification range should be 97 to 
103% (± 3%) [15]. For simplifying, all measured 
values (Yf) of LM preparations were calculated as 
% to label claim.
According to USP 41 <1225> [10], accuracy 
was evaluated by determining the % recovery 
(R) of the LM preparations, and evaluating the 
linearity between the regression curve Yf versus 
true or nominal concentration (Yc); the confidence 
interval (CI) of slope (Vaf) and intercept (Vbf) 
were calculated according to the method of Funk 
et al. [10,14,16]. Mean R ̅ was defined as the ratio 
Ȳf to Yc times 100%. The accuracy method that 
described by USP 41 <1225> [10] was identical to 
the method of Indonesian Pharmacopoeia V [8].
  USP 41 <1210> [11] described the method 
for estimating accuracy and precision, and 
combined validation of accuracy and precision. 
For estimating the accuracy and precision 
independently, confidence interval (CI) of bias (β) 
and standard deviation (U) of the LM preparations 
were determined.
β was 100 (1-2α) % two-sided confidence 
interval of bias, S was standard deviation, n was 
replications, and t(1-α:n-1) was percentile of 
central t-distribution with area 1-α to the left and 
n-1 degrees of freedom [11].
where U was an upper (100-α) % confidence 
bound for S,x2α:n-1was a percentile of central 
chi-square distribution with area α to the left and 
n-1 degrees of freedom [11].
Combined validation of accuracy and precision 
was performed by calculating the prediction 
interval (PI) and tolerance interval (TI) of Yf. 
Reportable value (Ȳf ± PI or TI) must be included 
in pre-determined specification range of the ATP.
where t(1+P)/2 was percentile of a central 
t-distribution with area (1+P)/2 to the left and 
(n-1) degrees of freedom [11].
where Z2(1+P)/2 was standard normal percentile 
with area α to the left, x2α:n-1was chi-square 
percentile distribution with area α to the left and 
(n-1) degrees of freedom [11].
In order to evaluate the accuracy and precision 
of bioassays, USP 41 <1033> [13] described a term 
of capability process (CP) and out of specification 
(OOS). This CP approach may be used simply, as a 
guide for simultaneously evaluation of accuracy 
and precision of chemical drugs, as described by 
Kromidas [17]. Evaluation of (OOS) was applied 
to predict the percentage that may fall outside the 
specification range. 
Where USL was upper specification limit, LSL was 
lower specification limit.
where ϕ presents the standard normal cumulative 
distribution function
All S in equations 1-6 were calculated as 
intermediate precisions (IP), and standard 
deviation of the mean (SDM) i.e. the root of the 
variance of the mean (VM) [12,15,18].
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where Sr2 was within condition variance (MS 
within), Sr was repeatability, SB2 was between 
condition variance (VarianceRun).
MSbetween and MSwithin can be obtained via ANOVA, n 
was number of replications for each run. 
where N was the number of runs.
2.6.4. Robustness 
In order to evaluate the robustness of the 
proposed method, the influence of small variations 
of three factors of the HPLC’s conditions (2.5) on 
the % recovery of LM2, were evaluated by using 
a Plackett-Burman design (Table 2); the three 
factors were column heater temperature, flow 
rate, and pH of the mobile phase. Analysis of 
effect of those factors was performed according 
to the method of Gonzales et al. [15,19].
Calculation of IP, SDM, CI, PI, TI, and robustness 
evaluation were carried out manually or by 
using Microsoft excel 2010, Quick Calcs – graph 
Pad [20], statpages.info/tolintvl [21], and self-
developed software (VMAR). The validity of the 
VMAR was evaluated by using Microsoft excel and 
calculator.
3. Results and discussion
3.1. Method validation
3.1.1. Selectivity
Extract of the blank of the LM preparations 
showed no peaks. The HPLC chromatogram of the 
extracts of LM2 showed two peaks of LH and HC. 
Figure 1 showed the typical HPLC chromatograms 
of standards, extract of LM2, and blank sample. 
For confirming the purity of the analyte’s peak, 
RSD of tailing factor (T) and total plate numbers 
(N) of peaks LH and HC of standards and LM2, 
were observed by six different wavelengths (220, 
225, 230, 235, 237, 240 nm); the RSD were 0.28, 
0.94% (T), 0.17, 0.70% (N), respectively. This 
showed that all analyte peaks were relatively 
pure due to their almost identical T and N values 
[14]. This simple method of peak purity checking 
can be applied at QC laboratory, especially in the 
countries in which the facilities of QC laboratories 
are generally limited. 
System suitability was evaluated by six 
replicate injections of standards solutions of LH 
(1000 µg/mL) and HC (250 µg/mL); RSD of RTs 
of LH and HC were 0.1% (<2%), whilst for peak 
areas were 0.6% and 0.7% (<2%), respectively; 
tailing factors were mean ± RSD (0.598±0.2%) 
Table 2. Design of experiment for robustness evaluation of LM2




pH of the 
mobile phase
R R of HC (%)
1 26.0 0.9 6.1 103.6 101.9
2 26.0 1.1 5.9 99.5 97.7
3 24.0 1.1 6.1 105.8 98.9
4 24.0 0.9 5.9 100.0 98.7
5 26.0 0.9 6.1 99.5 96.9
6 26.0 1.1 5.9 103.3 100.2
7 24.0 1.1 6.1 102.0 99.0
8 24.0 0.9 5.9 103.5 101.7
R: recovery
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Figure 1. Typical HPLC chromatogram (at 220 nm) of extract of the blank sample (a), extract of LM2 
suppositories (b), standards solutionof LH and HC (c)
were compared to fresh solutions) expressed as 
mean ± RSD, n = 4.
3.1.2. Linearity
Using this HPLC system, the linearity of LH and 
HC were achieved in the range of 600.0 to1500.0 
µg/ml and 160.0 to 360.0 µg/ml, respectively. 
The linear regression line equation for LH was Y= 
and (0.980±0.6%) (<2), respectively; total 
plate numbers were mean ± RSD (2647±0.4%) 
and (64682±0.7%) (>2000), respectively. The 
solutions of standard and LM2’s extract were 
stable for at least 24 h; the results of analysis 
were 100.29±0.81% (standard LH), 100.43±1.0% 
(sample LH), 99.82±0.60% (standard HC) and 
100.27±0.81% (sample HC). Data (peak areas 
aConfidence range of intercept (α = 0.05)
bConfidence range of slope (α = 0.05)
Table 3a. Accuracy evaluation of LH according to the USP 41 <1225>
Parameters Day 1 (n = 18) Day 2 (n = 18) Day 3 (n = 18)
R ̅±SD 100.9±0.70 101.3±0.95 100.7±0.36
Recovery curve’s equation Yf =-1.1972 + 1.0213Yc Yf=-0.48056 + 1.0179Yc Yf =-0.34444 + 1.0100Yc
R 0.9991 0.9982 0.9998
V afa -1.1972±2.3495 -0.48056±3.2235 -0.34444±1.1918
V bfb 1.0213±0.023188 1.0179±0.031814 1.0100±0.011762
Table 3b. Accuracy evaluation of HC according to the USP 41 <1225>
Parameters Day 1 (n = 18) Day 2 (n = 18) Day 3 (n = 18)
R ̅±SD 101.1±0.96 100.0±0.88 100.0±0.80
Recovery curve’s equation Yf = -1.4639 + 1.0254Yc Yf = -1.1389 + 1.0117Yc Yf = -1.8389 + 1.0183Yc
R 0.9983 0.9986 0.9990
Vafa -1.4639±3.2136 -1.1389±2.9128 -1.8389±2.4185
Vbfb 1.0254±0.031716 1.0117±0.028747 1.0183±0.023869
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Table 5.  Separate evaluations of accuracy and precision according to the USP 41 <1210> (in % of label claim)
Parameters LM1 (n = 18) LM2 (n = 18) LM3 (n = 18)
LH HC LH HC LH HC
Sr 0.68 0.91 0.42 0.41 0.98 1.03
IP 0.77 1.07 0.44 0.68 1.00 1.15
SDM 0.27 0.39 0.13 0.33 0.26 0.38
Table 4. Results of precision of LM preparations
Sr: repeatability
IP: intermediate precision
SDM: standard deviation of the mean

















































b: S, calculated as IP or SDM
c: CI of β were determined by equation 1 (α = 0.05)
d: U were by equation 2 (α = 0.05)
Table 6. Combination evaluation of accuracy and precision according to the USP 41 <1210> (in % of label claim)














































a : Specification range (Yc± 3%)
b : S, calculated as IP or SDM
c : PI (equation 3, p = 90%)
d : TI (equation 4, p = 95% and α = 0.10)
e : Out of specification
15234x + 423330, n = 5, relative process standard 
deviation Vxo was 0.39%, r = 0.9999, calculated 
testing value Xp (for p = 0.05) was 33.6 µg/ml (< 
600 µg/ml), for HC Y= 54500x + 1259000, Vxo 
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0.92%, r = 0.9997, Xp (for p = 0.05) was 20.8 µg/
ml (< 160 µg/ml). The residuals were distributed 
at random around the regression line; neither 
trend nor unidirectional tendency was found. 
This linear calibration curve showed variance 
homogeneity over the whole range. All the linear 
regression calibration curve parameters used 
in this present work for accuracy, precision and 
robustness evaluations showed satisfactory 
results (r> 0.99), Xp < lowest level of the 
calibration standards, Vxo (<5%) [14,16].
3.1.3. Accuracy and precision 
Table 3 demonstrated the high accuracy as 
revealed by the percentage of R ̅ and SD of LH 
and HC in three different days (< ±3% and < 
2%, respectively). To prove whether systemic 
errors did not occur, linear regression of the 
recovery curves Yf  against Yc were evaluated. All r 
values of the regression curves showed (> 0.99), 
confidence interval of the intercept (Vaf) and 
slope (Vbf) were not significantly different from 
zero (0) and one (1), respectively as requested by 
USP 41 <1225> [10,14,16].
Table 4 showed that all precision evaluations 
of LM preparations (repeatability, intermediate 
precision, and SDM) yielded value less than 2%. 
Sr was expressed the precision in one condition 
Table 7. Results of Cp, Cpk, and OOS of LM
a : S, calculated as IP or SDM
b : Out of specification





























































Figure 2. Regression line of Cp/Cpk1/Cpk2 Vs of TI,  : Cp,   : CPk1,   : CPk2
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(day), whereas IP stated precision in different 
days/conditions. SDM showed the standard 
deviations of the means in three conditions 
(day). For the evaluation of precision in different 
conditions, IP was recommended instead of SDM.
Table 5 showed the results of evaluation of 
accuracy and precision separately according to 
USP 41 <1210> (data in % of label claim) [11]. 
For calculating CI of β and U (equations 1 and 2), 
IP and SDM were applied respectively, for S. All CI 
of β falls entirely within the specification range of 
±3%, and U values were less than 2%.
Table 6 showed the results of combined 
evaluation of accuracy and precision using the 
methods of USP 41 <1210> (data in % of label 
claim) [11] all data of Ȳf ± PI included in the 
specification range (Yc ± 3%), if S was calculated 
as TI, 4 data were out of specification of ± 3%, 
but still included in the specification range of 
± 5%. These results showed the application of 
combination accuracy and precision was more 
sensitive compared to separate evaluation, as 
showed by Table 3 and 5.
Data CP and OOS that were presented in the 
Table 7 confirmed the results of Table 6. If the 
values of Cp and CPK were >1, all data of (Ȳf ± PI 
or TI) were inside the specification range. Figure 
2 showed the negative correlation between TI and 
CP/CPk; regression line equation was Y = 2.7423 
- 0.71827X (r = -0.86191, r table = 0.5897, n = 18, 
α = 0.01). Although some data of CP, Cpk, and Ȳf 
± TI showed unacceptable results, the OOS were 
still < 3 %. This present work showed the new 
validation methods of USP 41 <1210> [11] can be 
replaced by simpler method of capability process 
(Cp) as described by USP 41 <1033> [13] and 
Kromidas [17] CP/CPk method showed identical 
results to the new method of USP 41 <1210> [11].
3.1.4. Robustness
The results of % recovery of robustness 
evaluations was presented in Table 2. Analysis 
of effect according to the method of Gonzales et 
al. [15,19] showed that three described factors 
(column heater temperature, flow rate, and pH of 
the mobile phase) did not affect the results of the 
% recovery (data not shown).These data proved 
that the proposed method was robust.
4. Conclusions 
This present work showed that the proposed 
HPLC method is suitable for the simultaneous 
determination of LH and HC in suppositories. 
This HPLC method is more efficient compared to 
the densitometric method. The HPLC method is 
simple, selective, rapid, accurate and robust, and 
it was validated according to the new method of 
USP 41. Combined evaluation of accuracy and pre­
cision is recommended as a tool for QC, instead of 
separate determination. It seemed that method 
of CP/CPk that described by USP 41 <1033> for 
bioassays might be applied for chemical drugs as 
well; this work showed that both methods of USP 
41 <1210> and <1003> yielded identical results. 
Due to its simplicity, capability process method 
is recommended as a tool at the QC laboratory of 
the pharmaceutical industry.
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